Samarium-153Sm-EDTMP as an equivalent variant to pharmaceutical analgesic treatment
dc.creator | Tsoucalas, G. | en |
dc.creator | Sarafianou, E. | en |
dc.creator | Galanos, A. | en |
dc.creator | Parpa, E. | en |
dc.creator | Baziotis, N. | en |
dc.creator | Sgantzos, M. | en |
dc.creator | Gennimata, V. | en |
dc.creator | Lymperi, M. | en |
dc.creator | Patiraki, E. | en |
dc.creator | Kouloulias, V. | en |
dc.creator | Mystakidou, K. | en |
dc.date.accessioned | 2015-11-23T10:52:20Z | |
dc.date.available | 2015-11-23T10:52:20Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 11070625 | |
dc.identifier.uri | http://hdl.handle.net/11615/34058 | |
dc.description.abstract | Purpose: Cancer pain is the most serious symptom for patients, especially during their terminal phase, when palliative medicine is needed. Our study tried to verify the usefulness of single-shot intravenous administration of Samarium (Sm)-153EDTMP in patients with bone metastases (group-A, N=53, males=25, females=28, age range: 30-69 years), as well as to compare a series of variables, using as a control group (group-B, N=37, males=17,females=20, age range: 30-69 years) with patients who were under drug treatment given from a physician specialized in palliative medicine. Methods: Both groups answered the following questionnaires: Greek Brief Pain Inventory (GBPI), Brief Multidimensional Life Satisfaction Scale (BMLSS), Hospital Anxiety Depression Scale (HADS) and ECOG performance status. Results: Pain severity and pain interference improvement p=0.0005 for both groups. HADS-anxiety: Samarium group, p= 0.397, drugs group p= 0.031. HADS-depression improvement for both groups p=0.031 and p=0.003, respectively. BMLSS improvement p=0.029 and p=0.265, while EGOG PS improvement was p=0.005 and p=0.014, respectively (numeric values). Conclusion: Intravenous administration of Sm-153EDT-MP was equivalent to drug treatment against cancer pain for patients with multiple bone metastasis, an option for those patients who are intolerant or resistant to drug treatment. Samarium-treated patients needed less or not at all pain killers, having a better cost-effective result. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84921905350&partnerID=40&md5=c573220e0dd3fd6cd0963d80970d776f | |
dc.subject | Anxiety | en |
dc.subject | Cancer pain | en |
dc.subject | Depression | en |
dc.subject | Quality of life | en |
dc.subject | Samarium (Sm-153EDTMP) | en |
dc.subject | fentanyl | en |
dc.subject | lexidronam samarium sm 153 | en |
dc.subject | morphine | en |
dc.subject | paracetamol | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | analgesic activity | en |
dc.subject | Article | en |
dc.subject | assessment of humans | en |
dc.subject | bone marrow toxicity | en |
dc.subject | bone metastasis | en |
dc.subject | Brief Multidimensional Life Satisfaction Scale | en |
dc.subject | Brief Pain Inventory | en |
dc.subject | cancer palliative therapy | en |
dc.subject | cancer patient | en |
dc.subject | comparative study | en |
dc.subject | controlled study | en |
dc.subject | female | en |
dc.subject | Hospital Anxiety and Depression Scale | en |
dc.subject | human | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | pain assessment | en |
dc.subject | pain severity | en |
dc.subject | rating scale | en |
dc.subject | recommended drug dose | en |
dc.subject | remission | en |
dc.subject | single drug dose | en |
dc.subject | treatment duration | en |
dc.subject | treatment response | en |
dc.title | Samarium-153Sm-EDTMP as an equivalent variant to pharmaceutical analgesic treatment | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |